




Glutamine Prior Authorization

Drug Applied:	glutamine
---------------	-----------

Criteria:

Drug Applied will be approved when the requested medication is being used for an FDA approved indication and all of the following criteria are met:

I. Initial Therapy Criteria

A. Sickle cell disease as indicated by chart notes within past 180 days


1. Patient is using the requested agent to reduce the acute complications of sickle cell disease **and**
2. Patient is 5 years of age or older **and**
3. **ONE** of the following
 - a) Patient has been optimized on hydroxyurea for 3 months and will continue therapy **or**
 - b) Patient is unable to take hydroxyurea due to a contraindication or intolerance as indicated by chart notes
4. Patient has had 2 or more sickle cell crises within the past 12 months **and**
5. Chart notes and/or prescriber do not provide documentation that patient will be using the requested agent in combination with Adakveo (crizanlizumab-tmca) for the requested indication **and**
6. Prescriber is a specialist or has consulted with a specialist in the area of the patient's diagnosis (e.g., hematology)

Approval Duration: 12 months

II. Continued Therapy Criteria

A. Sickle cell disease as indicated by chart notes within past 12 months

1. Patient is using the requested agent to reduce the acute complications of sickle cell disease **and**
2. Patient is 5 years of age or older **and**
3. Documented clinical benefit since starting the requested agent (i.e., reduction/stabilization in acute complications of sickle cell disease) **and**
4. Chart notes and/or prescriber do not provide documentation that patient will be using the requested agent in combination with Adakveo (crizanlizumab-tmca) for the requested indication
5. Prescriber is a specialist or has consulted with a specialist in the area of the



patient's diagnosis (e.g., hematology)

Approval Duration: 12 months

References:

1. Endari prescribing information. Emmaus Medical, Inc. June 2025
2. Droxia prescribing Information. Bristol-Myers Squibb Company. July 2021.
3. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4:2656-2701.
4. Niihara Y, Miller ST, Kanter J, et al; Investigators of the Phase 3 Trial of L-Glutamine in Sickle Cell Disease. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018.

Policy Owned by: Curative PBM team